Interview with Robert Karl, Managing Director, MSD Russia
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Address: MSD Pharmaceuticals, Shabolovka 10, 119049, Moscow,Russia
Tel: +7 495 916-7100
Web: http://www.merck.com/index.html
About MSD
Today’s MSD is a global healthcare leader working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching programs that donate and deliver our products to the people who need them. For more information, visit www.msd.com. MSD is a tradename of Merck & Co., Inc., with headquarters in Whitehouse Station, N.J., U.S.A.
About MSD in Russia
In Russia, MSD is committed of developing innovative, first-in-class products, improving health and saving lives of Russian citizens. MSD in Russia is dedicated to science and scientific excellence, focusing on clinical research activities in the country. MSD products have been available in Russia for many years. In Russia, the company was recently renamed into MSD Pharmaceuticals LLC.
About MSD in Emerging Markets
In the Emerging Markets, MSD is currently ranked #5 by market share among multinational companies (IMS Health 2009); this ranking includes Asia Pacific, Latin America, Eastern Europe, Middle East and Africa. For MSD, Emerging Markets are defined as the following regions and countries: Asia Pacific, China, Latin America, Brazil, Eastern Europe and Middle East and Africa, including Russia.
MSD’s current portfolio and R&D focus are complementary to important disease areas with pressing public health issues in Emerging Markets: infectious diseases, vaccinations, cardiovascular disease, diabetes, women’s health and respiratory.
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here